U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C27H33N3O6S
Molecular Weight 527.632
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GLIQUIDONE

SMILES

COC1=CC=C2C(=C1)C(=O)N(CCC3=CC=C(C=C3)S(=O)(=O)NC(=O)NC4CCCCC4)C(=O)C2(C)C

InChI

InChIKey=LLJFMFZYVVLQKT-UHFFFAOYSA-N
InChI=1S/C27H33N3O6S/c1-27(2)23-14-11-20(36-3)17-22(23)24(31)30(25(27)32)16-15-18-9-12-21(13-10-18)37(34,35)29-26(33)28-19-7-5-4-6-8-19/h9-14,17,19H,4-8,15-16H2,1-3H3,(H2,28,29,33)

HIDE SMILES / InChI

Molecular Formula C27H33N3O6S
Molecular Weight 527.632
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: http://edudrugs.com/G/Glurenorm/more.html | http://www.e-compendium.be/topdf/1969/spc/H | http://www.rlsnet.ru/mnn_index_id_183.htm

Glurenorm is an anti-diabetic drug in the sulfonylurea class. It is used in the treatment of diabetes mellitus type 2. It is an ATP-dependent K+ (KATP) channel blocker. This block causes a depolarization which leads to activation of voltage-dependent Ca channels and Ca2+ influx, and eventually increases insulin release. Minor skin allergies, gastric upsets and other non-specific side effects have been reported. Hypoglycaemic reactions have been reported but they are infrequent. Glurenorm effect increase butadion, chloramphenicol, tetracycline, coumarin derivatives, cyclophosphamide, sulfonamides, MAO inhibitors, thiazide diuretics, beta-blockers, salicylates, alcohol.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Glurenorm

Approved Use

Used in the treatment of diabetes mellitus type 2.
PubMed

PubMed

TitleDatePubMed
Effect of pH and complexation on transdermal permeation of gliquidone.
2002 Sep
[Severe hypoglycemia in diabetics with impaired renal function].
2003 Feb 7
Effect of glurenorm on immunohistochemical changes in pancreatic beta cells of rats in experimental diabetes.
2005 Mar
Spectrophotometric method for quantitative determination of gliquidone in bulk drug, pharmaceutical formulations and human serum.
2006 Jul
Determination of glibenclamide in human plasma by liquid chromatography and atmospheric pressure chemical ionization/MS-MS detection.
2007 Feb 1
Determination of glycyrrhizin in dog plasma by liquid chromatography-mass spectrometry and its application in pharmacokinetic studies.
2010
Simultaneous determination of gliquidone, fexofenadine, buclizine, and levocetirizine in dosage formulation and human serum by RP-HPLC.
2010 May-Jun
Patents

Sample Use Guides

45-60 mg daily in divided doses taken before meals. Maximum single dose 60 mg, maximum daily dose 180 mg.
Route of Administration: Oral
In Vitro Use Guide
Gliquidone inhibits the [3H]glibenclamide (0.5 nM) binding to the rat cortex membranes (0.5-0.8 mg/ml) – IC50=27.2 nM.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:29:37 GMT 2023
Edited
by admin
on Fri Dec 15 15:29:37 GMT 2023
Record UNII
C7C2QDD75P
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
GLIQUIDONE
INN   MART.   MI   WHO-DD  
INN  
Official Name English
ARDF 26
Code English
gliquidone [INN]
Common Name English
GLURENORM
Brand Name English
GLIQUIDONE [MART.]
Common Name English
Gliquidone [WHO-DD]
Common Name English
GLIQUIDONE [MI]
Common Name English
ARDF-26
Code English
1-CYCLOHEXYL-3-(((P-(2-(3,4-DIHYDRO-7-METHOXY-4,4-DIMETHYL-1,3-DIOXO-2(1H)-ISOQUINOLYL)ETHYL)PHENYL)SULFONYL)UREA
Systematic Name English
Classification Tree Code System Code
WHO-ATC A10BB08
Created by admin on Fri Dec 15 15:29:37 GMT 2023 , Edited by admin on Fri Dec 15 15:29:37 GMT 2023
WHO-VATC QA10BB08
Created by admin on Fri Dec 15 15:29:37 GMT 2023 , Edited by admin on Fri Dec 15 15:29:37 GMT 2023
NCI_THESAURUS C97936
Created by admin on Fri Dec 15 15:29:37 GMT 2023 , Edited by admin on Fri Dec 15 15:29:37 GMT 2023
Code System Code Type Description
PUBCHEM
91610
Created by admin on Fri Dec 15 15:29:37 GMT 2023 , Edited by admin on Fri Dec 15 15:29:37 GMT 2023
PRIMARY
MERCK INDEX
m5748
Created by admin on Fri Dec 15 15:29:37 GMT 2023 , Edited by admin on Fri Dec 15 15:29:37 GMT 2023
PRIMARY Merck Index
SMS_ID
100000092780
Created by admin on Fri Dec 15 15:29:37 GMT 2023 , Edited by admin on Fri Dec 15 15:29:37 GMT 2023
PRIMARY
ECHA (EC/EINECS)
251-463-2
Created by admin on Fri Dec 15 15:29:37 GMT 2023 , Edited by admin on Fri Dec 15 15:29:37 GMT 2023
PRIMARY
EPA CompTox
DTXSID4023096
Created by admin on Fri Dec 15 15:29:37 GMT 2023 , Edited by admin on Fri Dec 15 15:29:37 GMT 2023
PRIMARY
DRUG BANK
DB01251
Created by admin on Fri Dec 15 15:29:37 GMT 2023 , Edited by admin on Fri Dec 15 15:29:37 GMT 2023
PRIMARY
CAS
33342-05-1
Created by admin on Fri Dec 15 15:29:37 GMT 2023 , Edited by admin on Fri Dec 15 15:29:37 GMT 2023
PRIMARY
DRUG CENTRAL
1302
Created by admin on Fri Dec 15 15:29:37 GMT 2023 , Edited by admin on Fri Dec 15 15:29:37 GMT 2023
PRIMARY
ChEMBL
CHEMBL383634
Created by admin on Fri Dec 15 15:29:37 GMT 2023 , Edited by admin on Fri Dec 15 15:29:37 GMT 2023
PRIMARY
WIKIPEDIA
GLIQUIDONE
Created by admin on Fri Dec 15 15:29:37 GMT 2023 , Edited by admin on Fri Dec 15 15:29:37 GMT 2023
PRIMARY
RXCUI
25793
Created by admin on Fri Dec 15 15:29:37 GMT 2023 , Edited by admin on Fri Dec 15 15:29:37 GMT 2023
PRIMARY RxNorm
FDA UNII
C7C2QDD75P
Created by admin on Fri Dec 15 15:29:37 GMT 2023 , Edited by admin on Fri Dec 15 15:29:37 GMT 2023
PRIMARY
MESH
C010969
Created by admin on Fri Dec 15 15:29:37 GMT 2023 , Edited by admin on Fri Dec 15 15:29:37 GMT 2023
PRIMARY
INN
3308
Created by admin on Fri Dec 15 15:29:37 GMT 2023 , Edited by admin on Fri Dec 15 15:29:37 GMT 2023
PRIMARY
EVMPD
SUB07928MIG
Created by admin on Fri Dec 15 15:29:37 GMT 2023 , Edited by admin on Fri Dec 15 15:29:37 GMT 2023
PRIMARY
NCI_THESAURUS
C72798
Created by admin on Fri Dec 15 15:29:37 GMT 2023 , Edited by admin on Fri Dec 15 15:29:37 GMT 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY